In a phase I/II study, voxelotor safely decreased hemolysis and red cell sickling in patients with mild disease.
BRAFV600E- and BRAFV600K-mutated melanomas responded differently to the two types of therapy.
Normalization of the platelet count was significantly faster with caplacizumab than with placebo.
The presence of CTCs 5 years after diagnosis was associated with a 13-fold higher risk for recurrence.
The rate of major complications was significantly lower with hybrid minimally invasive esophagectomy than with conventional transthoracic open esophagectomy.
Luspatercept increased hemoglobin and reduced transfusion burden in a phase II study.
Diagnosing and treating patients with VWF levels in the range of 30 to 50 IU/dL.
Image-based screening detected pancreatic malignancies in some high-risk individuals.
MSI may be a biomarker for checkpoint inhibitor response.
FOLFIRINOX significantly improved survival but increased toxicity.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.
Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.
Progression-free survival was prolonged with front-line brigatinib versus crizotinib.
Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.
Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.
Two-year overall survival was significantly improved with durvalumab versus placebo.
Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.
Progression-free survival was significantly longer with olaparib than with placebo.
Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.
Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.